Biliary Atresia (BA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Biliary Atresia (BA) Market Outlook
Thelansis’s “Biliary Atresia (BA)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Biliary Atresia (BA) treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Biliary
Atresia (BA) Overview
Biliary
atresia (BA) is a progressive, idiopathic, necroinflammatory process initially
involving a segment or all of the extrahepatic biliary tree. As the disease
advances, the extrahepatic bile duct lumen is obliterated, and bile flow is
obstructed, resulting in cholestasis and chronic liver damage. With time, the
intrahepatic biliary system becomes involved. Two different forms of BA are
recognized. The more common of the two forms is the perinatal or postnatal
form, which accounts for most cases. These children typically appear healthy at
birth; their weights are average, and they have pigmented stools. Jaundice
develops at some variable interval postnatally; typical timing is between 2 to
6 weeks of age. Because of the frequency of breast milk jaundice, the diagnosis
can be missed unless a fractionated bilirubin is obtained. The less common
presentation is the embryonic or fetal form, which occurs in 10% to 35% of
cases. These children are cholestatic at birth; 10% to 20% have associated
congenital anomalies. Neither of the two forms is thought to be inherited
because HLA identical twins discordant with BA have been described, and
recurrence within the same family is exceedingly rare.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment